Mind Medicine (mindmed) INC Form 4 insider transactions
Definium Therapeutics' Chief Legal Officer, Mark Sullivan, sold 10,702 common shares at a weighted average price of $18.47 to cover tax obligations from vested restricted stock units.
Definium Therapeutics CEO Robert Barrow sold 24,431 common shares on March 25, 2026, to cover tax obligations from vested restricted stock units.
Definium Therapeutics, Inc. Chief Financial Officer Brandi Roberts was granted 150,000 restricted stock units, vesting quarterly starting June 2026.
Definium Therapeutics' Chief Legal Officer, Mark Sullivan, was granted 125,000 Restricted Stock Units, vesting quarterly starting June 2026.
Definium Therapeutics' Chief Medical Officer, Daniel Karlin, was granted 150,000 restricted stock units, aligning executive incentives with long-term company performance.
Definium Therapeutics CEO Robert Barrow was granted 320,000 restricted stock units, increasing his beneficial ownership to 1,098,477 common shares.
Definium Therapeutics director Roger Adsett received a grant of 50,000 stock options with a vesting schedule over three years.
Mind Medicine's Chief Medical Officer, Daniel Karlin, sold 5,600 common shares for $13.1469 each to cover tax obligations related to vested restricted stock units.
MindMed CEO Robert Barrow sold 25,791 common shares on December 26, 2025, to cover tax obligations from vested restricted stock units.
Mind Medicine's Chief Legal Officer, Mark Sullivan, sold 11,276 common shares on December 26, 2025, to cover tax obligations from vested restricted stock units.
Mind Medicine (MindMed) Inc.'s Chief Legal Officer, Mark Sullivan, sold 11,278 common shares at $9.77 each to cover tax obligations related to vested restricted stock units.
Mind Medicine (MindMed) Inc. CEO Robert Barrow sold 25,797 common shares at $9.77 each to cover tax obligations, as part of a pre-arranged 10b5-1 plan.
Mind Medicine (MindMed) Inc.'s Chief Medical Officer, Daniel Karlin, sold 7,704 common shares to cover tax obligations related to vested restricted stock units.
Mind Medicine (MindMed) Inc.'s Chief Medical Officer, Daniel Karlin, sold 7,848 common shares at a weighted average price of $6.80 to satisfy tax withholding obligations related to vested restricted stock units.
Mind Medicine (MindMed) Inc. CEO Robert Barrow sold 26,491 common shares on June 25, 2025, at a weighted average price of $6.80 per share, primarily to cover tax obligations related to vested restricted stock units.
Mark Sullivan, Chief Legal Officer of Mind Medicine (MindMed) Inc., sold 11,491 common shares on June 25, 2025, to satisfy tax withholding obligations related to vested restricted stock units.
Mind Medicine (MindMed) Inc. Director Andreas Krebs was granted 75,187 stock options with an exercise price of $7.3, vesting monthly over a year or earlier upon the company's annual meeting.
Mind Medicine (MindMed) Inc. Director Carol A. Vallone was granted 75,187 stock options with an exercise price of $7.3 per share, aligning her interests with shareholder value.
Mind Medicine (MindMed) Inc. director Suzanne Louise Bruhn was granted 75,187 stock options with an exercise price of $7.3, as disclosed in a recent SEC Form 4 filing.
Mind Medicine (MindMed) Inc. Director Roger Crystal was granted 75,187 stock options with an exercise price of $7.30, vesting monthly over a year or sooner under certain conditions.
Mind Medicine (MindMed) Inc. Director David W. Gryska was granted 75,187 stock options with an exercise price of $7.3 per share, vesting monthly over a year or earlier under specific conditions.
Mind Medicine (MindMed) Inc.'s Chief Financial Officer, Brandi Roberts, was granted 500,000 stock options with an exercise price of $7.26, aligning her incentives with long-term shareholder value.
MindMed's CEO, Robert Barrow, sold 21,208 common shares on March 25, 2025, to cover withholding tax obligations related to vested restricted stock units.
Daniel Karlin, Chief Medical Officer of Mind Medicine (MindMed) Inc., sold 6,836 common shares on March 25, 2025, to cover withholding tax obligations related to vested restricted stock units.
Mark Sullivan, Chief Legal Officer of Mind Medicine (MindMed) Inc., sold 6,576 common shares on March 25, 2025, to cover withholding tax obligations related to vested restricted stock units.
Carrie Liao, Chief Accounting Officer of Mind Medicine (MindMed) Inc., reports the sale of 2,347 common shares to cover withholding tax obligations related to vested restricted stock units.
Form 4: Mind Medicine (MindMed) Inc.: Chief Commercial Officer Matthew T. Wiley Reports Stock Option Grant
Matthew T. Wiley, Chief Commercial Officer of Mind Medicine (MindMed) Inc., reports the acquisition of stock options for 350,000 common shares.
MindMed's CEO, Robert Barrow, reports the acquisition of 350,000 restricted stock units and shares acquired through the Employee Share Purchase Plan.
Form 4: MindMed's Chief Medical Officer, Dan Karlin, Reports Acquisition of 115,000 Restricted Stock Units
Dan Karlin, Chief Medical Officer of Mind Medicine (MindMed) Inc., reports the acquisition of 115,000 restricted stock units (RSUs) on March 12, 2025.
Mark Sullivan, Chief Legal Officer of Mind Medicine (MindMed) Inc., reports the acquisition of 150,000 restricted stock units (RSUs) on March 12, 2025.